Abstract. Somatostatin is well known to inhibit the hormone secretion of various peptides. This action has been considered to be generally mediated via six different specific somatostatin receptors (sstr), sstr1, sstr2A, sstr2B, sstr3, sstr4, and sstr5. It then becomes very important to demonstrate the localization of these sstr subtypes in order to elucidate the possible biological and/or clinical significance of somatostatin actions. These sstr subtypes have been demonstrated to be expressed throughout the human body, including the central nervous system, gastrointestinal tract, pancreas, kidney, and other organs, but its details, especially its systemic distribution and localization in tissue compartments, have yet to be examined thoroughly in human. Therefore, in this study, we examined the systemic localization of all six somatostatin receptors in normal human organs using immunohistochemistry with recently developed specific antibodies against these receptor subtypes. In all of the human tissues examined, various sstr subtypes were detected not only in parenchymal cells but also in various stromal cells such as lymphocytes, fibroblasts, and endothelial cells. Among human tissues in which the presence of sstr has not been previously reported, the parotid gland demonstrated immunoreactivity for sstr2B and sstr5, bronchial gland for sstr1, 2B, 3, 4, 5, parathyroid gland for sstr1, 3, 4, and duodenum for all subtypes immunoreactivity. The great majority of other organs examined demonstrated results consistent with those of previously reported biochemical studies. In pancreatic islet cells, only sstr2A was positive in all the cases but other sstr subtypes were associated with marked intraislet heterogeneity in their distribution. In stomach, all subtypes of receptor were detected in various cell types of the mucosa, but none in ECL cells of fundic gland. These findings demonstrated the broad systemic actions of somatostatin in non-endocrine cells.
SOMATOSTATIN is a 14-or 28-amino acid peptide that was originally discovered in 1973 as a hypothalamic neuroendocrine hormone [1] . This peptide was first considered to inhibit the secretion of growth hormone from the anterior pituitary gland, but the presence of this peptide hormone was subsequently detected throughout the body, where it inhibits a number of physiological processes through suppression of various peptide hormones, such as pancreatic secretion, neurotransmission in the central nervous system, and gut motility [2] . The actions of somatostatin in these tissues have been demonstrated to be mediated by six specific somatostatin receptors (sstr), sstr1, sstr2A, sstr2B, sstr3, sstr4, and sstr5. These receptors belong to a family of seven transmembrane domain G-proteincoupled receptors encoded on five different chromosomes. Among these receptor subtypes, sstr2A and sstr2B are encoded on the same chromosome 17, and are generated through alternative splicing of the sstr2 mRNA [3] . These six receptor subtypes all share common signal pathways such as the inhibition of adenylyl cyclase [4] , activation of phosphotyrosine phosphatase and others, but some subtypes are also associated with modulation of inward rectifying K+ channels (sstr2, 3, 4, 5) , to voltage-dependent Ca2+ channels (sstr1, 2), and a Na+/H+ exchanger (sstr1) [4] .
The presence of these sstr subtypes has also been demonstrated throughout the body, including the central nervous system [5] , gastrointestinal (GI) tract [6, 7] , pancreas [8] [9] [10] , kidney [11] , and other organs. It then becomes very important to determine which subtypes of the receptor somatostatin exert their effects on which cells of the human body, but to date the systemic cellular distribution of these receptor subtypes has not been reported to the best of our knowledge. In particular, in situ examination of sstr subtypes expression is considered to be very important because sstr subtypes have been reported in lymphoid cells [12] [13] [14] [15] , macrophages [16] , fibroblasts [17, 18] and blood vessel cells [19, 20] which are generally present in all the tissues throughout the body. This finding also makes it nearly impossible to obtain precise data on the distribution of sstr subtypes when employing methods such as RT-PCR which treat the tissue as a mass. Therefore in this study, we examined systemic distribution of sstr subtypes in human normal tissues obtained from surgery or autopsy by immunohistochemistry using recently developed specific polyclonal antibodies against there subtypes of sstr.
Materials and Methods

Human tissues
Non-pathological human tissue specimens were retrieved from surgical and/or autopsy pathology files of Department of Pathology, Tohoku University Hospital, Sendai, Japan. Cases of systemic inflammatory disease, metastatic carcinoma, or endocrine disorders were excluded from this study. After reviewing surgical pathology specimens under light microscopy, only morphologically normal tissue were examined in this study. The tissues had been fixed in 10% buffered formalin and embedded in paraffin. This research protocol (No 2004-107) was approved by the Ethics Committee of Tohoku University School of Medicine.
Antibody against somatostatin receptor subtype
For immunohistochemistry, all rabbit polyclonal antisstr subtype antibodies were commercially obtained from Gramsch Laboratories (Schwabhausen, Germany). Dilution of the antibodies used was 1:2000 for ss-840 (sstr1), ss-800 (sstr2A), ss-860 (sstr2B), ss-850 (sstr3) and ss-890 (sstr5). Ss-880 (sstr4) was used at a concentration of 2 mg/ml. Specificity of antibody was confirmed by blocking with its cognate peptide provided by the supplier. Positive control experiments included normal human pancreas and/or anterior pituitary gland obtained from surgery and autopsy, respectively. To further determine the co-localization of sstr subtypes and hormones in GI tract, immunostaining on serial tissue sections with mirror images was employed in this study. Chromogranin was examined in order to determine the correlation between enterochromaffinlike (ECL) cells and sstr in GI tract.
Immunohistochemistry
Immunohistochemistry was performed with the streptavidin-biotin-amplified method using a Histofine Kit (Nichirei, Tokyo Japan). Ten percent formalinfixed, paraffin-embedded tissue blocks were serially cut into 3 mm thick sections which were then dewaxed in xylene and rehydrated through a graded series of ethanol. The method of antigen retrieval was determined by comparing the findings obtained by autoclave treatment for 5 min at 120°C and microwave treatment for 15 min at 600 W. In addition, we also tried to compare the findings between a 0.01 M citric acid buffer (pH 6) and H-buffer in this treatment. We selected an incubation of the tissue sections in 0.01 M citric acid buffer (pH 6) and autoclaving for 5 min at 120°C prior to immunohistochemical procedures based on the results of the above procedures (data not shown). Non-specific binding sites were blocked through pre-incubation of normal goat serum. Reacted tissue sections were then incubated with the antibodies for each sstr subtype for 18 hours at 4°C. Endogenous peroxidase activity was quenched by incubating the section in 1% hydrogen peroxide for 30 min at room temperature. Antigenantibody complex was subsequently visualized with 3,3-diaminobenzidine (DAB) solution (1 mM DAB, 50 nM Tris/HCl buffer {pH 7.6, and 0.006% H 2 O 2 }). and counterstained with hematoxylin.
Results
Results are summarized in Table 1 . Immunoreac-tivity was primarily detected in the cytoplasm and/or cell membrane in all sstr subtypes. Pancreatic islet cells, which have been employed as a positive control in immunostaining, demonstrated immunoreactivity for all subtypes of sstr examined, which is consistent with results of previous studies [8, 10] . Anterior pituitary gland also demonstrated immunoreactivity for all subtypes of sstr ( Fig. 1a ) except for subtype 4, which was also consistent with the results by Panetta and Patel [21] .
Immunoreactivity for all sstr subtypes was detected in lymphocytes, macrophages, fibroblasts, and endothelial cells of the vessels, in all the tissues examined. The number of sstr positive cells in lymphocytes generally showed a rank order of sstr1, sstr2B>sstr5, sstr3>sstr2A>>sstr4. Both monocytes and macrophage also demonstrated marked sstr2A immunoreactivity. Endothelium of blood vessel was also associated with sst1, sst2B and sst5 immunoreactivity (Fig. 1b) .
Parotid gland demonstrated immunoreactivity for sstr2B and sstr5 in acinar cells of serous gland. In addition, sstr3 immunoreactivity was only detected in ductal cells, but not in acinar cells (Fig. 1c) . Thyroid gland demonstrated sstr2B, 3 and 5 immunoreactivity in follicular epithelium (Fig. 1d) , but not in parafollicular on C cells. Sstr1, 3 and 4 immunoreactivity was also detected in chief cells of parathyroid gland, but not in oxyphil cells. Immunoreactivity for all sstr subtypes was detected in tracheal gland except for sstr2A, but not in epithelial cells of trachea (Fig. 1e) .
In stomach, surface mucous cells demonstrated no immunoreactivity for sstr, but gastric foveolae were positive for all subtypes of sstr. Immunohistochemistry with chromogranin in serial tissue sections with mirror images demonstrated that those sstr positive cells corresponded to non-ECL cells (Fig. 2a, b) . On the other hand, some sstr3 positive cells were also immunopositive for chromogranin in small intestine (Fig. 2c, d ). In duodenum, immunoreactivity for all subtypes of sstr was detected in Brunner's gland. Immunoreactivity was also detected in mucinous cells and a few ductal cells (Fig. 1f) . Epithelial cells of small intestine, colon, and rectum demonstrated sstr1, 2A, 2B, and 5 immunoreactivity (Fig. 1g) . Immunoreactivity for all sstr subtypes was detected in pancreatic islets, but only 2 out of 7 cases were positive for sstr4, while sstr4 and sstr5 were detected in some acinar cells ( Fig. 2e, f, g ). In liver, hepatocytes demonstrated immunoreactivity for sstr5, and cholangiocytes for sstr1, 2A and 2B. In kidney, some cells in the glomeruli demonstrated immunoreactivity for sstr1 and 2A, which morphologically corresponded to the mesangial cells. Distal tubules were associated with all sstr subtypes examined except for sstr3 (Fig. 1h) .
Discussion
This is the first report to demonstrate systemic sstr subtype immunolocalization in human organs other than the central nervous system. In our present study, we detected immunoreactive sstr2A primarily at the cell membrane, but immnoreactivity for other sstr subtypes was detected primarily in the cytoplasm and at the membrane. Cytoplasmic sstr is generally considered to represent either newly synthesized or internalized membrane receptor protein [22] . However, further investigations are required to elucidate the biological and/or clinical significance of this cytoplasmic localization of sstr. In all human tissues examined in our study, all subtypes of sstr were universally expressed in lymphocytes, though their relative abundance was different among receptor subtypes. Previous studies have demonstrated various sstr subtype expressions in lymphocytes [13] [14] [15] [16] , which also suggest that somatostatin may regulate the process of lymphocyte activation. Curtis et al. and Badway et al. independently demonstrated sstr1 and sstr2 expression in endothelial cells [19, 20] . Precise actions of somatostatin on endothelial cells have not yet been clarified, but somatostatin may be involved in regulating endothelial cell homeostasis and anti-inflammatory effects [20] . The results of our present study clearly indicated that in situ analysis, such as immunohistochemical study, is required for detecting precise localization of sstr in human physiological and/or pathological condition.
In this study, the patterns of somatostatin receptor subtypes varied among the different human endocrine or epithelial cells (Table 1 , 2). Further investigations are needed to clarify whether these differences are due to individual variations or the conditions of fixation in each tissue specimen.
In thyroid gland, somatostatin is well known to regulate thyroid hormone secretion through the inhibition of thyroid-stimulating hormone release in pituitary [23, 24] , but the existence of direct inhibitory mechanisms upon the secretion from follicular cells has remained controversial. Ain et al. revealed the existence of sstr in human normal thyroid gland using RT-PCR study [25] , in which sstr3 and sstr5 m-RNA expression was abundant while sstr2 was extremely low and other sstr subtypes were absent. These findings were consistent with the results of our present study. In addition, the findings in the present study also demonstrated that possible actions of somatostatin through sstr2 are mainly mediated through sstr2B expressed in epithelial cells of thyroid follicular cells.
In parathyroid glands, exact distribution of each sstr subtype has not been examined. The results of our present immunohistochemical study demonstrated that the chief cells of the parathyroid gland expressed sstr1, 3, and 4. Lucarotti et al. reported that octreotide, a somatostatin analogs, improved hypercalciuria and reduced urinary stone formation in patients with primary hyperparathyroidism [26] . While this effect may be due to the direct suppressive action of somatostatin on parathyroid hormone secretion, the exact mechanism awaits further elucidataion.
Several studies have been performed on the possible effects of somatostatin on gastric function in the rat model. Somatostatin has been reported to mediate acid secretion in the stomach by activation of sstr2 expressed in gastric mucosa [27] [28] [29] [30] . The results of our present immunohistochemical study on human stomach also demonstrated the presence of all receptor subtypes in gastric fundal gland. However, rat gastric ECL cells were reported to express sstr2B [32] , while ECL cells were negative for all types of receptor subtypes in human gastric mucosa.
In small intestine, sstr1, sstr3, and sstr5 immunoreactivity was also detected in the fundic gland. These immunoreactive cells are considered to correspond to Paneth cells. Some sstr3 immunoreactive cells were considered to be ECL cells as a result of chromogranin immunostaining on serial tissue sections with mirror section. The possible effects of somatostatin on Paneth and ECL cells in small intestine have not been well characterized. Kimura et al. also reported that crypt cells of mucosa of GI tract were positive for sstr2A [32] . Laws et al. [33] and Raggi et al. [6] reported the presence of sstr2 and sstr5 and Hope et al. [34] also reported sstr1 in colonic mucosa using RT-PCR. In our present study, both colonic and rectal mucosa demonstrated not only sstr2A immunoreactivity but also sstr1, 2B and 5 in the great majority of crypt cells of GI tract. Possible roles of somatostatin in intestinal tract are generally considered to include the suppression of chloride secretion [35, 36] which is related to clinical treatment of octreotide for controlling secretory diarrhea [37] [38] [39] .
Sstr has been extensively studied in pancreatic islets. In the pancreas, sstr2 was expressed in alpha cells and sstr5 in beta cells [8] [9] [10] 40] . However, Kumar et al. reported that the number of sstr3 and sstr4 positive cells were relatively small [8] while Portela-Gomes et al. reported that sstr1, 3, 4 were expressed in the great majority of islet cells using immunohistochemistry [10] . In our present study, sstr2A was constantly detected in all the cases examined. While the great majority of alpha cells and many of beta cells demonstrated sstr2A immunoreactivity, delta cells did not.
In other sstr subtypes, the patterns of immunolocalization varied among individuals. Sstr5 tended to be immunolocalized in the great majority of beta cells and some alpha cells and delta cells. Sstr3 tended to be present in the great majority of alpha cells and some beta cells, but not in delta cells (Fig. 2f, g ). Sstr 1, 2B and 4 were diffusely present in islet cells (Fig. 2e) . Results of these findings in islet cells of human pancreas were consistent with previously reported studies [8, 10] . Octreotide generally delivers a good clinical outcome for patients with pancreatitis or prevents pancreatitis after intervention to pancreatic duct in those patients [41] [42] [43] [44] , but its mechanism was not well characterized. The results of our present study suspected that octreotide action through sstr4 and sstr5 may play important roles in the regulation of pancreatic juice secretion in acinar cells of pancreas.
In summary, immunohistochemical analysis of sstr subtype could provide important information as to the modes of action of somatostatin in human tissues, and its possible application as a surrogate marker of octreotide treatment in pathological conditions merits further investigation.
